WTAP ‐Mediated m 6 A Modification of circSMOC1 Accelerates the Tumorigenesis of Non‐Small Cell Lung Cancer by Regulating miR ‐612/ CCL28 Axis
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Xun-Xia Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Huadong Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, RNA, Circular, MicroRNAs, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Accumulating evidence reveals that deregulated N6‐methyladenosine (m 6 A) RNA methylation and circular RNAs (circRNAs) are required for the tumorigenesis of non‐small cell lung cancer (NSCLC). We aimed to uncover the underlying mechanisms by which WTAP‐mediated m 6 A modification of circRNA contributes to NSCLC. The differentially‐expressed circRNAs were identified by a circRNA profiling microarray. The association of circSMOC1 with clinicopathological features and prognosis in patients with NSCLC was estimated by fluorescence in situ hybridization. WTAP‐mediated m 6 A modification of circRNA was validated by RNA immunoprecipitation (RIP) and methylated RIP (MeRIP) assays. The role of circSMOC1 in NSCLC cells was validated by in vitro functional experiments and in vivo tumorigenesis models. CircSMOC1‐specific binding with miR‐612 was verified by RIP, luciferase gene report and RT‐qPCR assays. The effect of circSMOC1 and/or miR‐612 on CCL28 expression was detected by RT‐qPCR and Western blotting analysis. We found that the expression levels of circSMOC1 were elevated in NSCLC tissues and associated with TNM stage and poor survival in patients with NSCLC. Knockdown of circSMOC1 impaired the tumorigenesis of NSCLC in vitro and in vivo, whereas restored expression of circSMOC1 displayed the opposite effect. Furthermore, WTAP was upregulated in NSCLC and mediated m 6 A modification of circSMOC1 and circSMOC1 abolished WTAP knockdown‐caused tumour‐suppressive effects. Then, circSMOC1 acted as a sponge of miR‐612 to upregulate CCL28 and miR‐612 inhibitors abrogated circSMOC1 knockdown‐caused anti‐proliferation effects and CCL28 downregulation in NSCLC cells. Knockdown of CCL28 inhibited cell proliferation and invasion and counteracted miR‐612 inhibitor‐caused tumour‐promoting effects. Our findings unveil that WTAP‐mediated m 6 A modification of circSMOC1 facilitates the tumorigenesis of NSCLC by regulating the miR‐612/CCL28 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Huadong Hospital, Fudan University, Shanghai, China.
- Department of Nursing, Huadong Hospital, Fudan University, Shanghai, China.
- Department of Critical Care Medicine, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
ORCID-Profile: Xiao-Yong Shen
Zitieren
APA
Zhu, X. X., Chen, X. Y., Zhao, L. T., Zhang, X. L., Li, Y. O., & Shen, X. Y. (2024). WTAP ‐Mediated m 6 A Modification of circSMOC1 Accelerates the Tumorigenesis of Non‐Small Cell Lung Cancer by Regulating miR ‐612/ CCL28 Axis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70207
Vancouver
Zhu XX, Chen XY, Zhao LT, Zhang XL, Li YO, Shen XY. WTAP ‐Mediated m 6 A Modification of circSMOC1 Accelerates the Tumorigenesis of Non‐Small Cell Lung Cancer by Regulating miR ‐612/ CCL28 Axis. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70207
BibTeX
@article{Zhu2024,
author = {Zhu, Xun-Xia and Chen, Xiao-Yu and Zhao, Li-Ting and Zhang, Xue-Lin and Li, Yi-Ou and Shen, Xiao-Yong},
title = {WTAP ‐Mediated m 6 A Modification of circSMOC1 Accelerates the Tumorigenesis of Non‐Small Cell Lung Cancer by Regulating miR ‐612/ CCL28 Axis},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70207}
}
EUVIMED